Hi, I have a sister, 48 years old, Gabriela, that was diagnosed with Ovarian neoplasm – (17.12.2013) and she was undertaken a surgery -ovarian adenocarcinoma cyst(total hysterectomy, bilateral anexectomy, rectosigmoidian resection, right diagraphragmatic and prerenal pelvic peritonectomy, parcelar resection of a right diaphragm and omenectomy) T3cN1M1 PLE M1 LYM M1PER M1OTH(diaphragm) – stage IV(01.2014), PCT. Also Gabriela received 12 sessions of chemotherapy with Carboplatin + Taxol(2014), performed re-evaluation(PET/CT scan which showed disease progression) and started chemotherapy with Caelyx. On 20.01.2015 she has the 2nd session of treatment with Caelyx but her marker Ca125 riches a high value of 1400. So the second line of treatment failed . Wondering if you could help me with some info about the 3rd line of treatment for her case and what are the chances/prognostic for her please? I would very much appreciate an answer from you. Warmest regards from Sydney, Elle 
                                                        
                                                     
                                                    
                                                        
                                                            
                                                            
                                                            
                                                                posted on
                                                            
                                                                Tue, 24 Feb 2015 
                                                            
                                                            
                                                            
                                                            
                                                                
                                                                    
                                                                    
                                                                    Sun, 25 Nov 2018
                                                                    
                                                                    
  Answered on 
                                                                 
                                                                
                                                                    
                                                                    
                                                                    Tue, 27 Nov 2018
                                                                    
                                                                    
  Last reviewed on